SPOTLIGHT: Toyama seeks early flu pact


Japan's Toyama Chemical is looking to do a development and marketing rights deal on a promising, early-stage bird flu therapy in order to gin up some revenue. Any pact prior to proof-of-concept is likely to go at a discount. Report